Spots Global Cancer Trial Database for Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer
Official Title: Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) Vopratelimab (JTX -2011) and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer
Study ID: NCT03989362
Conditions
Study Description
Brief Summary: JTX-2011-201 is a Phase 2, open label clinical study of vopratelimab (JTX-2011) and ipilimumab in adult subjects with non-small cell lung cancer (NSCLC) or urothelial cancer to evaluate safety and efficacy.
Detailed Description: Vopratelimab (JTX-2011) is an agonist monoclonal antibody that specifically binds to the Inducible CO-Stimulator of T cells (ICOS) to generate an anti-tumor immune response. This is a Phase 2, open label study to evaluate the safety and efficacy of vopratelimab in combination with ipilimumab in adult subjects with advanced and/or refractory non-small cell lung cancer and urothelial cancer.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beverly Hills Cancer Center, Beverly Hills, California, United States
University of Southern California Medical Center, Los Angeles, California, United States
Christiana Care Health Services, Newark, Delaware, United States
Florida Cancer Specialists Sarasota Cattlemen, Sarasota, Florida, United States
University of Maryland - Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
The Valley Hospital, Ridgewood, New Jersey, United States
Weill Cornell Medical College, New York, New York, United States
University of Rochester, Rochester, New York, United States
Southeastern Medical Oncology Center, Clinton, North Carolina, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Allegheny Health Network Research Institute, Pittsburgh, Pennsylvania, United States
Lifespan Cancer Institute, Providence, Rhode Island, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
University of The Texas Health Science Center at San Antonio, San Antonio, Texas, United States
University of Virginia Health System, Charlottesville, Virginia, United States
University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada
The Research Institute of the McGill University Health, Montréal, Quebec, Canada
University Institute of Cardiology and Respirology of Quebec, Québec, , Canada
Contact Details
Name: Ellen Hooper, MD
Affiliation: Jounce Therapeutics, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
